{
    "clinical_study": {
        "@rank": "151555", 
        "arm_group": [
            {
                "arm_group_label": "onabotulinumtoxinA Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "Up to 4 treatments of onabotulinumtoxinA Dose 1 injected into muscles of the study limb on fulfillment of the retreatment criteria."
            }, 
            {
                "arm_group_label": "onabotulinumtoxinA Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "Up to 4 treatments of onabotulinumtoxinA Dose 2 injected into muscles of the study limb on fulfillment of the retreatment criteria."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a long-term safety and efficacy study of onabotulinumtoxinA in poststroke patients\n      with upper limb spasticity."
        }, 
        "brief_title": "Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Muscle Spasticity", 
            "Stroke"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Muscle Spasticity", 
                "Stroke"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  For patients entering from the 191622-127 study, successful completion of study\n             191622-127\n\n          -  For patients entering directly into study 191622-129, upper limb spasticity in the\n             elbow and shoulder due to stroke, with the most recent stroke at least 3 months ago\n\n        Exclusion Criteria:\n\n          -  Spasticity in the non-study upper limb that requires treatment\n\n          -  Presence of fixed contractures in of the study muscles in elbow or shoulder\n\n          -  Profound atrophy of muscles to be injected\n\n          -  Previous surgical intervention, nerve block, or muscle block for the treatment of\n             spasticity in the study limb in the last 12 months\n\n          -  Injection of corticosteroids or anesthetics, use of casting or dynamic splinting or\n             constraint-induced movement therapy (CIMT) for the study limb within 3 months\n\n          -  Ultrasound therapy, electrical stimulation, or acupuncture in the study limb within 1\n             month\n\n          -  Condition other than stroke contributing to upper limb spasticity\n\n          -  Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, and/or amyotrophic lateral\n             sclerosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02145689", 
            "org_study_id": "191622-129", 
            "secondary_id": "2013-002327-42"
        }, 
        "intervention": {
            "arm_group_label": [
                "onabotulinumtoxinA Dose 1", 
                "onabotulinumtoxinA Dose 2"
            ], 
            "description": "Up to 4 treatments of onabotulinumtoxinA injected into muscles of the study limb on fulfillment of the retreatment criteria.", 
            "intervention_name": "onabotulinumtoxinA", 
            "intervention_type": "Biological", 
            "other_name": [
                "BOTOX\u00ae", 
                "botulinum toxin type A"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 21, 2014", 
        "link": {
            "description": "More Information", 
            "url": "http://www.allerganclinicaltrials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas"
                }
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in the Modified Ashworth Scale-Bohannon (MAS-B) Score of Treated Muscle Groups Using a 6-Point Scale", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Up to 60 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02145689"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Clinical Global Impression (CGI) of Overall Change by Physician Compared to Baseline Using a 9-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Up to 60 Weeks"
            }, 
            {
                "measure": "Change from Baseline in Pain on an 11-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Up to 60 Weeks"
            }, 
            {
                "measure": "Change from Baseline in the 19-Item Spasticity Impact Assessment-Upper Limb (SIA-UL) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Up to 60 Weeks"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}